Add BrightSurf on Google Email

Fred Hutchinson Cancer Center


Breaking the silence: Discovery could lead to new treatments for cancer, sickle-cell anemia

Scientists at Fred Hutchinson Cancer Center have discovered a potential new treatment for cancer and sickle-cell anemia by inhibiting gene silencing. The compound, splitomicin, effectively blocks the silencing of genes critical for healthy growth and may also be effective against certain cancers.

SourceFred Hutchinson Cancer Center·JournalProceedings of the National Academy of Sciences·DateDec 17, 2001

Fred Hutchinson Cancer Research Center investigator finds that transplant patients' newly-developed immune systems function effectively 20 to 30 years later

A study by Dr. Jan Storek found that long-term bone-marrow and stem-cell transplant survivors can live normal lives without frequent infections, with immunity recovering to normal within 20 years. The researchers also discovered that transplanted hematopoietic cells remain functional for at least 20-30 years.

Tag, you are it: A two-step approach to treating patients with multiple myeloma shows promise

A two-step approach combining high-dose chemotherapy and autologous stem-cell rescue with mini-transplantation from a sibling significantly reduces transplant-related complications and increases survival rates for patients with advanced-stage multiple myeloma. The procedure results in mild to moderate treatment-related toxicities and a...

Majority of pediatric cancer patients use alternative therapies: Fred Hutchinson Cancer Research Center survey

A recent survey conducted by the Fred Hutchinson Cancer Research Center found that nearly three-quarters of pediatric cancer patients in western Washington use alternative therapies. The most common types of alternative medicine used were herbal and high-dose vitamin supplements, which were reported to have substantial improvements in ...

SourceFred Hutchinson Cancer Center·JournalPreventive Medicine·DateOct 31, 2001

Researchers release results of study showing patients undergoing stem-cell transplantation live longer than those undergoing marrow transplantation

A study led by Dr. William Bensinger found that patients undergoing stem-cell transplantation lived longer than those receiving marrow transplants, especially for high-risk blood cancers. The study also showed lower rates of acute and chronic graft-versus-host disease with stem cells.

SourceFred Hutchinson Cancer Center·JournalNew England Journal of Medicine·DateJan 16, 2001

Some Americans, fed up with conflicting diet and nutrition messages, respond with less healthful eating habits

A study by researchers at the Fred Hutchinson Cancer Center found that people who feel frustrated with dietary recommendations are more likely to eat a fat-laden diet. The study, which surveyed 1,751 adults in Washington state, also found evidence of 'nutrition backlash,' where negative feelings about diet messages lead to unhealthy ea...

SourceFred Hutchinson Cancer Center·JournalJournal of the American Dietetic Association·DateDec 31, 2000

Fred Hutchinson researchers present preliminary clinical results with antibody to treat severe graft versus host disease

Researchers at Fred Hutchinson Cancer Center have shown promising results with a new antibody treatment, Nuvion, in patients with severe graft versus host disease. The study found that Nuvion was well-tolerated and achieved complete responses in six of nine patients who received a single dose.

SourceFred Hutchinson Cancer Center·JournalThe Journal of Immunology·DateDec 3, 2000

Antibody-targeted chemotherapy-induced remission and stem-cell transplantation prolong disease-free survival for leukemia patients

A study at the American Society of Hematology Meeting found that patients with acute myeloid leukemia who achieve remission with Mylotarg have prolonged disease-free survival following stem cell transplantation. Researchers also observed fewer complications from bone marrow transplants compared to traditional treatment.

Fred Hutchinson Cancer Research Center's Puget Sound Oncology Consortium to participate in nationwide study to evaluate benefit of Herceptin therapy

The Puget Sound Oncology Consortium is partnering with the National Surgical Adjuvant Breast and Bowel Project to evaluate Herceptin therapy in women with early stage breast cancer. The trial, Protocol B-31, aims to assess the safety and efficacy of combining Herceptin with chemotherapy in treating node-positive breast cancer patients.

Former Fred Hutchinson Cancer Research Center marrow transplant patients to celebrate life at a reunion in Seattle

Hundreds of former bone marrow transplant survivors from the Fred Hutchinson Cancer Research Center will gather in Seattle for a reunion, sharing memories and hopes for the future. The event is part of the center's 25th anniversary celebration and includes activities such as presentations on latest research findings and workshops.

Fred Hutchinson Cancer Research Center Study shows novel agent can prevent transplant reactions and promote immunological tolerance

Researchers at Fred Hutchinson Cancer Research Center have discovered a novel agent that can prevent transplant reactions and promote immunological tolerance. The treatment, using an anti-CD28 antibody, could lead to safer and more effective transplants, reducing the risk of graft-versus-host disease.

SourceFred Hutchinson Cancer Center·JournalThe Journal of Immunology·DateMay 1, 2000

New molecular 'dowsing' technique could more quickly and precisely lead researchers to key drug targets

A new molecular engineering technique, inspired by centuries-old concept of principal axes of inertia, can help researchers identify functional regions on proteins crucial for drug delivery. This method may aid in developing molecular-modeling software to streamline the search process.

SourceFred Hutchinson Cancer Center·JournalProceedings of the National Academy of Sciences·DateJan 30, 2000

Building detailed map of human DNA will take more time and resources than previously thought, says Hutch researcher

A detailed map of the human genome will require locating at least half a million genetic markers to be useful for pharmaceutical research and development. According to Dr. Leonid Kruglyak, researchers need to locate more genetic markers to stay on track when chasing down genes that influence disease susceptibility and drug response.

SourceFred Hutchinson Cancer Center·JournalNature Genetics·DateMay 31, 1999